Literature DB >> 22507207

Evaluation of a synthetic C34 trimer of HIV-1 gp41 as AIDS vaccines.

Chie Hashimoto1, Wataru Nomura, Aki Ohya, Emiko Urano, Kosuke Miyauchi, Tetsuo Narumi, Haruo Aikawa, Jun A Komano, Naoki Yamamoto, Hirokazu Tamamura.   

Abstract

An artificial antigen forming the C34 trimeric structure targeting membrane-fusion mechanism of HIV-1 has been evaluated as an HIV vaccine. The C34 trimeric molecule was previously designed and synthesized using a novel template with C3-symmetric linkers by us. The antiserum produced by immunization of the C34 trimeric form antigen showed 23-fold higher binding affinity for the C34 trimer than for the C34 monomer and showed significant neutralizing activity. The present results suggest effective strategies of the design of HIV vaccines and anti-HIV agents based on the native structure mimic of proteins targeting dynamic supramolecular mechanisms in HIV fusion.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507207     DOI: 10.1016/j.bmc.2012.03.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Sulfono-γ-AA modified peptides that inhibit HIV-1 fusion.

Authors:  Olapeju Bolarinwa; Meng Zhang; Erin Mulry; Min Lu; Jianfeng Cai
Journal:  Org Biomol Chem       Date:  2018-10-31       Impact factor: 3.876

2.  Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.

Authors:  Olfa Mzoughi; Meritxell Teixido; Rémi Planès; Manutea Serrero; Ibtissem Hamimed; Esther Zurita; Miguel Moreno; Giovana Granados; Faouzi Lakhdar-Ghazal; Lbachir BenMohamed; Ernest Giralt; Elmostafa Bahraoui
Journal:  Biosci Rep       Date:  2019-09-24       Impact factor: 3.840

Review 3.  Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Authors:  Kenji Maeda; Debananda Das; Takuya Kobayakawa; Hirokazu Tamamura; Hiroaki Takeuchi
Journal:  Curr Top Med Chem       Date:  2019       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.